chufangao/CTO huggingface dataset:
Clinical trial NCT03235180: Ultrasound Evaluation of Crohn's Disease
Official title: Ultrasound Evaluation of Crohn's Disease
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Unable to secure funding.
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-16
Primary completion date: 2021-10-12
Completion date: 2021-10-12
Plan to share individual participant data: NO
Clinical trial NCT04740970: A Study of JNJ-64304500 in Participants With Alopecia Areata
Official title: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-64304500 in Patients With Alopecia Areata
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor Decision.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-24
Primary completion date: 2022-06-02
Completion date: 2022-07-20
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04137887: Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older
Official title: Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine Versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Enrollment terminated due to the COVID-19 pandemic
Enrollment: 33096.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-04
Primary completion date: 2020-05-31
Completion date: 2020-05-31
Baseline population: Analysis was performed on all vaccinated participants.
Limitations and caveats: COVID-19 severely impacted the study resulting in low influenza circulation and disruption of trial recruitment for subsequent seasons (no enrollment done for seasons 2020-21 \& 2021-22). Moreover, the events collected as primary outcomes could have been driven by COVID cases, diluting the effect of influenza vaccines on such events. The study was prematurely terminated.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04403282: Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial
Official title: Topical Eflornithine Hydrochloride for Pseudofolliculitis Barbae: A Randomized, Double-blinded, Placebo-controlled Trial
Sponsor: Walter Reed National Military Medical Center (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Vaniqa no longer manufactured
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-27
Primary completion date: 2023-06-22
Completion date: 2023-06-22
Plan to share individual participant data: NO
IPD sharing description: The PI will compile the names of the patients who are followed through week 16 in order to create the master subject list. Using the information stored on the master subject list (name, social security number, Medical Record Number), the research team will obtain data electronically from the patient medical records. Specifically, the lesion and hair counts on the face will be acquired. This will be recorded on the master data sheet. The master subject list will be password protected and only accessible to study personnel within the Walter Reed National Military Medical Center (WRNMMC) network. The master data sheet will be coded and available to the investigators and may be shared with research assistants or statisticians.
Clinical trial NCT03988647: Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
Official title: A Phase 2 Study of Palliative Radiation Therapy and Anti-PD-1/PD-L1 Checkpoint Blockade in Patients With Metastatic Merkel Cell Carcinoma
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-24
Primary completion date: 2020-11-16
Completion date: 2021-01-20
Plan to share individual participant data: NO
Clinical trial NCT02119000: Comparison of Two Types of Bowel Preparation for Inpatient Colonoscopy
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Difficulty in recruitment
Enrollment: 82.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-08-31
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Clinical trial NCT05084456: Oral Docetaxel in Patients With Normal or Impaired Liver Function
Official title: Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir in Patients With Normal or Impaired Liver Function
Sponsor: Modra Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Pending further development
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-07-31
Primary completion date: 2020-02-29
Completion date: 2020-04-30
Plan to share individual participant data: NO
Clinical trial NCT03417401: Surgical Stabilizer Assisted RVC With rtPA for CRVO
Official title: Phase Ib Study on Surgical Stabilizer Assisted Retinal Vein Cannulation (RVC) With tPA Infusion Confirmed by Intraoperative Angio-optical Coherence Tomography (Angio-OCT) for the Treatment of Central Retinal Vein Occlusion (CRVO).
Sponsor: Universitaire Ziekenhuizen KU Leuven (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: organizationally not yet possible
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-16
Primary completion date: 2021-12-10
Completion date: 2021-12-10
Plan to share individual participant data: NO
Clinical trial NCT03854032: Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Official title: Window-of-Opportunity Trial of Nivolumab and BMS986205 in Patients With Squamous Cell Carcinoma of the Head and Neck (CA017-087)
Sponsor: Thomas Jefferson University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: toxicity - per sponsor
Enrollment: 45.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-09
Primary completion date: 2024-06-12
Completion date: 2024-06-12
Clinical trial NCT03780725: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
Official title: An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 754111 in Patients With Advanced Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma Treated With BI 754111 in Combination With BI 754091
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to company decision.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-22
Primary completion date: 2020-02-19
Completion date: 2020-12-08
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:~1. studies in products where Boehringer Ingelheim is not the license holder;~2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;~3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).~For more details refer to: https://www.mystudywindow.com/msw/datasharing
Clinical trial NCT04328285: Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers
Official title: Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial
Acronym: COVIDAXIS
Sponsor: Centre Hospitalier Universitaire de Saint Etienne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: French authority's decision
Enrollment: 118.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-14
Primary completion date: 2020-05-13
Completion date: 2022-03-30
Plan to share individual participant data: NO
Clinical trial NCT04488185: An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
Official title: An Exploratory, Randomized, Double-blind, Parallel-group, Multicenter Study to Compare Secukinumab 300 mg With Placebo After 16 Weeks of Treatment in Adults With Moderate to Severe Plaque Psoriasis and Subclinical Enthesitis Measured by Musculoskeletal Ultrasound
Acronym: INTERCEPT
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: low recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-02
Primary completion date: 2021-03-24
Completion date: 2021-03-24
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03345004: Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
Official title: A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 Diabetes
Sponsor: Diamyd Medical AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 109.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-20
Primary completion date: 2020-07-13
Completion date: 2021-04-27
Clinical trial NCT00061282: Clotrimazole Enemas for Pouchitis in Children and Adults
Official title: Clotrimazole Enemas for Pouchitis in Children and Adults
Acronym: CAPTURE
Sponsor: Boston Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Funding Horizon
Enrollment: 11.0 (ACTUAL)
Number of arms: 3.0
Start date: 2002-09-30
Primary completion date: 2020-12-01
Completion date: 2020-12-01
Clinical trial NCT04946318: Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
Official title: A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 136.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-09-08
Primary completion date: 2022-09-08
Completion date: 2022-09-08
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04915950: A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 13.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-11-03
Primary completion date: 2022-09-02
Completion date: 2022-09-02
Baseline population: The full analysis set (FAS) included all randomized participants, irrespective of whether they received any study treatment.
Limitations and caveats: This study was terminated early due to a business decision that was not due to any safety concerns. The number of participants was smaller than originally planned and only summary statistics were therefore generated for primary and secondary outcome measures.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04872101: Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
Official title: A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2)
Acronym: DELTA 2
Sponsor: LEO Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 473.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-25
Primary completion date: 2022-12-27
Completion date: 2023-01-06
Plan to share individual participant data: YES
IPD sharing description: De-identified IPD can be made available to researchers in a closed environment for a specified period of time.
IPD time frame: Data is available to request after results of the trial are available on leopharmatrials.com
IPD access criteria: Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.
Clinical trial NCT03418480: HARE-40: HPV Anti-CD40 RNA vaccinE
Official title: Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma
Acronym: HARE-40
Sponsor: University of Southampton (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-11
Primary completion date: 2023-11-01
Completion date: 2024-01-24
Plan to share individual participant data: NO
Clinical trial NCT04776876: Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Official title: A Phase II, Open-Label, Single-Arm Study of INCMGA00012 and Telotristat Ethyl in Patients With Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study will not be opening. Support was withdrawn.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-01
Primary completion date: 2021-09-02
Completion date: 2021-09-02
Clinical trial NCT04748588: Treatment of Nosocomial COVID-19
Official title: Canadian Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Nosocomial Acquired COVID-19 Patients
Acronym: CATCO-NOS
Sponsor: University of Calgary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Equipoise requirement no longer met.
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-12
Primary completion date: 2022-01-31
Completion date: 2022-01-31
Plan to share individual participant data: NO
Clinical trial NCT03362593: A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses
Official title: A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, Including Assessment of the Impact of Changes to the Oral Formulation and Determination of Intravenous Pharmacokinetics
Sponsor: MedImmune LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The program is canceled due to company strategic reasons.
Enrollment: 186.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-12-04
Primary completion date: 2020-05-11
Completion date: 2020-05-11
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ standards.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
Clinical trial NCT03562507: Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
Official title: ERICA: Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
Acronym: ERICA
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of patient population
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-11
Primary completion date: 2022-10-18
Completion date: 2022-10-18
Baseline population: No patients were enrolled in the ESK984 and Nivolumab combo arm
Plan to share individual participant data: NO
Clinical trial NCT03580187: Nebulized Morphine in Chest Trauma Patients: A Prospective Study
Official title: Nebulized Morphine in Chest Trauma Patients: A Prospective Study
Sponsor: University Hospital, Mahdia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 75.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-14
Primary completion date: 2020-04-15
Completion date: 2020-04-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02582996: Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks
Official title: National, Phase III, Multicenter, Randomized, Open, Parallel, to Evaluate the Efficacy, Safety and Superiority of Cefalium® Compared to the Tylenol® in the Treatment of Migraine Attacks
Sponsor: Ache Laboratorios Farmaceuticos S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Strategic reasons of the company
Enrollment: 336.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2021-04-30
Completion date: 2021-06-30
Clinical trial NCT03554109: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
Official title: An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC
Acronym: TNBC
Sponsor: ImmunityBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Trial not initiated
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-30
Primary completion date: 2020-06-30
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT02077621: Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer
Official title: The Phase II Clinical Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer
Sponsor: PhytoHealth Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study reevaluation
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-02-28
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04565327: Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma
Official title: Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-14
Primary completion date: 2022-11-01
Completion date: 2022-11-01
Baseline population: No participants were assigned to Cohort A
Limitations and caveats: Study closed earlier than expected due to slow accrual
Plan to share individual participant data: NO
Clinical trial NCT04604132: Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
Official title: A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic Aberrations
Acronym: FIDES-03
Sponsor: Basilea Pharmaceutica (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated prematurely for administrative reasons not related to patient safety.
Enrollment: 47.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-10-06
Primary completion date: 2022-11-21
Completion date: 2022-11-21
Plan to share individual participant data: NO
Clinical trial NCT04691232: Autologous Ex Vivo Expanded Regulatory T Cells in Ulcerative Colitis
Official title: Phase I, Open-label, Fast-track Dose-escalation Clinical Trial Exploring the Safety and the Tolerability of Autologous ex Vivo Expanded Regulatory T Cells in Adults With Ulcerative Colitis
Sponsor: University of Erlangen-Nürnberg Medical School (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-22
Primary completion date: 2023-04-12
Completion date: 2023-05-22
Plan to share individual participant data: NO